Press Releases

Press Releases

Apr 5, 2011
Summary ToggleEnzon Presents Data at 2011 AACR Meeting
Third-Generation mRNA Antagonists Continue Showing Promise in Expanding Range of Oncology Indications Locked Nucleic Acid Technology to be Featured in RNA-Targeting Therapeutics Symposium PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.
Mar 17, 2011
Summary ToggleEnzon Appoints Richard Mulligan, Ph.D. Vice-Chairman of the Board; Adopts Majority Vote Standard for Election of Directors
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Richard C. Mulligan , Ph.D., has been appointed Vice-Chairman of the Board of Directors, effective immediately. Dr.
Feb 17, 2011
Summary ToggleEnzon Reports 2010 Results
Pipeline Development Continues to Advance as Transformation to a Biotechnology Company is Complete PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its fourth-quarter and full-year 2010 financial results.
Feb 10, 2011
Summary ToggleEnzon to Release Fourth Quarter 2010 Earnings on Thursday, February 17, 2011; Conference Call and Webcast to Follow
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it will report its financial results for the quarter ended December 31, 2010 , on Thursday, February 17, 2011 at 4:00 pm Eastern Time (ET).
Jan 10, 2011
Summary ToggleEnzon to Begin Phase 1 Study of Novel Androgen Receptor mRNA Antagonist in Castration-Resistant Prostate Cancer
BRIDGEWATER, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration ( FDA ) and plan to commence enrollment into a Phase 1a/ 1b study shortly.
Dec 21, 2010
Summary ToggleEnzon Board Authorizes Share Repurchase Program
BRIDGEWATER, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the Company's Board of Directors has authorized the purchase of up to $200 million of outstanding shares of the Company's common stock.
Dec 15, 2010
Summary ToggleEnzon Announces the Initiation of Two Phase I Studies in Collaboration with the National Cancer Institute
BRIDGEWATER, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute (NCI), for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
Nov 17, 2010
Summary ToggleEnzon Presents Data at 2010 EORTC-NCI-AACR Meeting
Third-Generation mRNA-Targeting Compounds Show Potent Anti-Tumor Activity BRIDGEWATER, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists.
Nov 2, 2010
Summary ToggleEnzon Reports Third Quarter 2010 Results
BRIDGEWATER, N.J., Nov 02, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the third quarter of 2010.
Nov 2, 2010
Summary ToggleEnzon Pharmaceuticals Awarded $1.2 Million in Grants under QTDP Program
BRIDGEWATER, N.J., Nov 02, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc.
Displaying 31 - 40 of 337 results